专注于代谢和内分泌疾病的临床阶段生物制药公司Lipocine Inc.

StephenW

SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be presented at The Liver Meeting® 2019.  The Liver Meeting® 2019, which is the annual meeting of the American Association for the Study of Liver Diseases ("AASLD"), a leading organization of scientists and healthcare professionals committed to preventing and curing liver disease, will be held on November 8th – 12th in Boston, Massachusetts.  Lipocine's abstract has been selected by the Scientific Program Committee of the AASLD as a Poster of Distinction for presentation.
(PRNewsfoto/Lipocine Inc.)
(PRNewsfoto/Lipocine Inc.)

Presentation Details
       

       

Title:
       

LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease

Publication Number:
       

#2121

Date:
       

Monday, Nov 11, 2019

Location:
       

John B. Hynes Memorial Convention Center

Time:
       

8AM – 5:30PM ET

About Lipocine

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men and currently under USFDA review for marketing approval. LPCN 1144, a differentiated oral product of bioidentical testosterone, is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients and recently completed a proof-of-concept clinical study demonstrating the potential utility the in treatment of NASH.  TLANDO XR (LPCN 1111), a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and has completed Phase 2 testing. LPCN 1148 is a unique oral testosterone product targeted to treat NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

StephenW

盐湖城，2019年10月1日/美通社/-专注于代谢和内分泌疾病的临床阶段生物制药公司Lipocine Inc.（LPCN）今天宣布，来自LPCN 1144的非酒精性脂肪病临床试验数据肝病（“ NAFLD”）将在The LiverMeeting®2019上发表。The LiverMeeting®2019是美国肝病研究协会（“ AASLD”）的年度会议，该协会是由美国致力于预防和治愈肝病的专业医护人员将于11月8日至12日在马萨诸塞州的波士顿举行。 Lipocine的摘要已被AASLD的科学计划委员会选为杰出表现者。
（PRNewsfoto / Lipocine Inc.）
（PRNewsfoto / Lipocine Inc.）

演讲内容




标题：


LPCN 1144解决了非酒精性脂肪肝疾病

出版编号：


＃2121

日期：


2019年11月11日星期一

位置：


约翰·海因斯纪念会议中心

时间：


美国东部时间上午8点–下午5:30

关于利波辛

Lipocine Inc.是一家临床阶段的生物制药公司，使用其专有的药物输送技术专注于代谢和内分泌疾病。 Lipocine的临床开发计划包括TLANDO，LPCN 1144，TLANDO XR（LPCN 1111），LPCN 1148和LPCN 1107开发计划。 TLANDO是一种含有十一酸睾丸酮的新型睾丸激素口服前药，旨在帮助恢复性腺功能减退男性的正常睾丸激素水平，目前正接受美国食品和药物管理局的审查，以上市许可。 LPCN 1144，一种与生俱来的睾丸激素不同的口服产品，目前正在接受活检证实的NASH患者进行2期临床测试，并且最近完成了一项概念验证的临床研究，证明了其在NASH治疗中的潜在效用。 TIPOO XR（LPCN 1111）是一种新型的睾丸激素口服前药，由Lipocine发明并正在开发，是下一代口服睾丸激素产品，具有每日一次给药的潜力，并已完成第二阶段测试。 LPCN 1148是用于治疗NASH肝硬化的独特口服睾丸激素产品。 LPCN 1107可能是第一个口服羟基黄体酮己酸酯产品，可用于预防复发性早产，并已被FDA授予孤儿药称号。与FDA的第二阶段会议已经结束。有关更多信息，请访问www.lipocine.com。